with a thiol compound has been described as increasing the solubility and antimicrobial properties of bismuth (Domenico et al. 1997; Veloira et al. 2003) . Bismuth thiols enhance in vitro immune response against Klebsiella pneumoniae and P. aeruginosa (Domenico et al. 1999; Wu et al. 2002; Alipour et al. 2010) . They also inhibit exopolysaccharide production (Domenico et al. 2001; Badireddy et al. 2008b) , resulting in decreased biofilm (Domenico et al. 2001; Badireddy et al. 2008a) . Additionally, bismuth thiols exhibit synergy with antibiotics (Veloira et al. 2003) . These properties indicate that bismuth thiols could make excellent antimicrobials.
If biofilms pose a barrier to healing in chronic wounds, then effective antibiofilm therapies may aid healing in these cases. Using established methods, we determine which of many possible bismuth thiols could be most effective in the treatment of biofilms formed by bacteria isolated from human chronic wounds.
Materials and methods

Chronic wound isolates
Methicillin-resistant Staphylococcus aureus 10943 (MRSA) and Pseudomonas aeruginosa #215 were obtained from the Southwestern Regional Wound Center (Lubbock, TX, USA). MRSA was grown statically overnight in tryptic soy broth (TSB; Becton Dickinson, Franklin Lakes, NJ) at 37°C, and P. aeruginosa was grown overnight in TSB at 37°C and 150 rev min )1 in 250-ml baffled Erlenmeyer flasks. Stock cultures were maintained at )70°C using Microbank vials (Pro-Lab diagnostics, Austin, TX, USA).
Antibiotics and antimicrobial agents
The antibiotics, imipenem monohydrate, cefepime HCl (U. S. Pharmacopeia, Rockville, MD, USA), rifampicin, vancomycin, tobramycin, ampicillin (Sigma-Aldrich chemical, St. Louis, MO, USA), ciprofloxacin (Fluka Biochemika, Sigma-Aldrich chemical), daptomycin (Cubist pharmaceuticals, Lexington, MA, USA), minocycline and amikacin (MP Biomedicals, LLC; Solon, OH, USA) were used for antibiotic susceptibility testing of biofilms. Bismuth thiol preparations (Table 1) were provided by Microbion Biosciences (Bozeman, MT, USA), and 5-mg ml )1 stocks was fresh prepared daily in DMSO.
Silver sulfadiazine (Spectrum Chemical, Gardena, CA) was prepared as 1% slurry in 0AE1% peptone or PBS.
Colony biofilm susceptibility
Colony biofilms were prepared according to Anderl et al. (2000) , with modifications. Briefly, overnight bacterial cultures were diluted in TSB to an OD 600 of 0AE05, and one 10-ll drop is placed onto sterile, black, polycarbonate membrane filters (K02BP02500; GE Water and Process Technologies, Trevase, PA). Prior to inoculation, the filters were applied to tryptic soy agar (TSA; Becton Dickinson) modified to contain only 10% of the usual amount of pancreatic digest of casein and papaic digest of soybean (10% TSA). Biofilms were grown for 24 ± 2 h, before being challenged with antimicrobial for 18 h. To determine biofilm antibiotic challenge levels, minimum inhibitory concentrations for the antibiotics including azithromycin, tetracycline and ampicillin ⁄ Sulbactam 2 : 1 were determined using E-test strips (AB Biodisk, Solna, Sweden). Colony biofilms were challenged with antibiotics, bismuth thiols and combinations of these treatments. The treatments were prepared in Mueller Hinton agar (Oxoid, Basingstoke, UK) plates amended with the desired treatment. For daptomycin challenge, we used BBL Mueller Hinton II agar (Becton Dickinson) supplemented with calcium chloride to a final concentration of Bismuth-1-mercapto-2-propanol (1 : 3) BisBDT ⁄ PYR Bismuth-2,3-butanedithiol ⁄ Bismuth-2-mercaptopyridine N-oxide (2 : 1 : 2) BisBAL ⁄ PYR Bismuth-2,3-dimercaptopropanol ⁄ Bismuth-2-mercaptopyridine N-oxide (2 : 1 : 2) BisEDT ⁄ PYR Bismuth-1,2-ethanedithiol ⁄ Bismuth-2-mercaptopyridine N-oxide (2 : 1 : 2) BisTOL ⁄ PYR Bismuth-4-methyl-1,2-benzenedithiol ⁄ Bismuth-2-mercaptopyridine N-oxide (2 : 1 : 2) BisPDT ⁄ PYR Bismuth-1,3-propanedithiol ⁄ Bismuth-2-mercaptopyridine N-oxide (2 : 1 : 2) BisERY ⁄ PYR Bismuth-dithioerythritol ⁄ Bismuth-2-mercaptopyridine N-oxide (2 : 1 : 2) BisHPT ⁄ EDT Bismuth-1-mercapto-2-propanol ⁄ Bismuth-1,2-ethanedithiol (1 : 1 : 1) 50 mg l )1 . Susceptibility assays were performed in at least duplicate.
Drip-flow biofilm susceptibility
Colony biofilms were used as a screening tool. Drip-flow biofilms, which are more complicated to prepare, were used to confirm effects of selected treatments. Drip-flow biofilms were prepared according to Xu et al. (1998) , with modifications. Briefly, the overnight culture of P. aeruginosa was diluted tenfold (OD 600 1), and MRSA was diluted fivefold (OD 600 1), with 10 ml of 0AE1% peptone and used to inoculate each channel of the drip-flow reactor (BioSurfaces Technologies Corp., Bozeman, MT, USA). Dakin fully frosted slides (no. 2958-001; Thermo Scientific, Portsmouth, NH, USA) were placed in each channel to provide a growth surface for the biofilms. After 2 h static incubation, biofilms were grown for 72 h at a flow rate of 10 ml h )1 per channel using L ⁄ S 13 tubing, with masterflex pumps (Cole Parmer, Vernon Hills, IL) operating at 2AE61 rev min )1 with TSB diluted tenfold for MRSA or 100-fold for P. aeruginosa. These growth conditions were based on a published protocol (Buckingham-Meyer et al. 2007 ). Growth and inoculation were performed at 37°C. Drip-flow biofilms were challenged for 24 h with selected bismuth thiols, selected antibiotics or 1% silver sulfadiazine. Antibiotics were used at 100 times the MIC, and bismuth thiols were applied at 40, 80, 200 and 500 lg ml )1 .
Antibiotics, silver sulfadiazine and bismuth thiol treatments for P. aeruginosa drip-flow biofilms were prepared in 20 ml of 0AE1% peptone and in PBS for S. aureus treatments. Treatments for drip-flow biofilms were applied to slides removed from the reactor and laid flat in a Petri dish. Susceptibility assays were performed in at least duplicate.
Viable cell enumeration
Biofilms were dispersed into 0AE1% peptone. Colony biofilms were transferred with the membrane and vortexed at maximum for 20 s, and drip-flow biofilms were dispersed by scraping with a Teflon policeman and agitation by hand. Dispersed biofilms were homogenized for 30 s at 11 500 rev min )1 (Ultra Turrax T25 S1;
IKA Labortechnik, Wilmington, DE), serially diluted in 0AE1% peptone water and enumerated by the drop method (Hoben and Somasegaran 1982; Herigstad et al. 2001) onto tryptic soy agar using 10-ll drops. Colonies were counted and marked daily with colonies appearing within 4 days counted. Bismuth thiols were neutralized with the addition of 2 g l )1 reduced glutathione (Acros Organics, Mullica Hill, NJ) to the dispersal medium and also to the plates used for enumeration.
Results
Colony biofilm susceptibility
Several antibiotics were tested against bacteria in colony biofilms to provide comparisons for the efficacy of bismuth thiols and to guide the selection of agents to be tested subsequently in combination with bismuth thiols. MICs were determined for planktonic P. aeruginosa and MRSA, and colony biofilms of each were challenged with ten or one hundred times the MIC. Colony biofilms of these strains were very tolerant to antibiotic treatment (Table 2 ). Ciprofloxacin killed 3AE5 log CFU within P. aeruginosa colony biofilms, while rifampicin killed approximately 1 log within MRSA colony biofilms. The other antibiotics were not effective in killing the colony biofilms. P. aeruginosa was resistant to azithromycin and tetracycline, and these antibiotics were not included in any further testing. Colony biofilms of P. aeruginosa and MRSA were challenged with several different bismuth thiols to identify those with the greatest bactericidal activity against biofilms (Table 3) . Efficacy ranged widely from no effect to several log reductions. The most efficacious bismuth thiol for each bacterial species performed better than the most efficacious antibiotic for that micro-organism. Overall, MRSA colony biofilms were less susceptible than those of P. aeruginosa (Fig. 1) . Bismuth thiols effective against one species did not usually display comparable efficacy, at the same dose concentration, against the other micro-organism (R 2 = 0AE15 for the data plotted in Fig. 1 ).
To identify antibiotics that yield synergy with bismuth thiols, we combined antibiotics with either 80 lg ml )1
BisEDT used to challenge P. aeruginosa colony biofilms or 200 lg ml )1 BisEDT for MRSA colony biofilms.
Combinations were considered to be synergistic if the log kill achieved by the combination was greater than the sum of the log kills achieved by the bismuth thiol and antibiotic separately. Tested under the conditions used in these studies, the combination of amikacin with BisEDT resulted in synergy (Table 4 ) when challenging P. aeruginosa colony biofilms, while with MRSA colony biofilms, no synergy was found with any of the combinations, and only the combination with rifampicin exhibited even marginal efficacy (Table 4) . Based on this information, P. aeruginosa and MRSA were challenged with other bismuth thiols combined with amikacin or rifampicin, respectively (Table 5 ). Six combinations of amikacin and bismuth thiols were effective against P. aeruginosa, four of which were synergistic combinations with BisBAL, Bis-BDT, BisTOL ⁄ PYR and BisHPT ⁄ EDT. For MRSA, two were effective with combinations of rifampicin and BisBAL or BisBDT ⁄ PYR being synergistic. Some of the bismuth thiol ⁄ antibiotic combinations tested were antagonistic.
Drip-flow biofilm susceptibility
The most effective bismuth thiols for each microorganism were tested in a second in vitro biofilm model system. The drip-flow biofilm reactor is a continuous flow system (Goeres et al. 2009 ). Bismuth thiols performed similarly or better against biofilms grown in Table 3 The effect of bismuth thiols on the viability of bacteria in colony biofilms
Bismuth thiol Log kill n SD P. aeruginosa colony biofilms treated with 80 lg ml
MRSA colony biofilms treated with 200 lg ml Biofilm efficacy of bismuth thiols J.P. Folsom et al.
the drip-flow reactor compared to the colony biofilm (Table 6 , Fig. 2 ). For both bacterial species, the most effective bismuth thiol outperformed or matched the most effective antibiotic or silver sulfadiazine treatment (Table 6 ). Most of the bismuth thiols exhibited the anticipated dose-response behaviour of increasing effectiveness with increasing concentration (Fig. 2) . The effectiveness of BisEDT ⁄ PYR against MRSA was opposite, declining from 4AE7 log CFU kill at 80 lg ml )1 to 0AE6 log CFU kill at 500 lg ml )1 . 
*Sum of the log kill of each agent individually for comparison. 
MRSA challenged with 100· MIC rifampicin plus indicated bismuth thiol 500 lg ml
*Sum of the log kill of each agent individually for comparison. Table 6 The effects of bismuth thiols and selected comparison treatments on the viability of bacteria in drip-flow biofilms 
Discussion
Choice of in vitro models
The in vitro biofilm models selected for this investigation were intended to simulate two physical aspects of the wound environment: low fluid shear and proximity to an air interface. The colony biofilm model also captures the expected geometry of nutrient delivery in a wound: carbon and nitrogen sources emanating from host tissue (agar in the model) with oxygen supplied from the opposite side of the biofilm. One reason to use two different models is that every model gives somewhat different results. Potential therapies that perform well in more than one in vitro model probably have a better chance of affording robust efficacy in real-world applications. We chose to work with strains of P. aeruginosa and S. aureus because these two bacteria are commonly identified in human chronic wounds (Fazli et al. 2009; Frank et al. 2009; Malic et al. 2009; Körber et al. 2010; Melendez et al. 2010; Thomsen et al. 2010) . In reality, chronic wounds are colonized by mixed populations of bacteria James et al. 2008; Kirketerp-Møller et al. 2008; Frank et al. 2009) . A logical next step for testing of bismuth thiols would be to evaluate their efficacy in a mixed species model (Percival et al. 2008; Sun et al. 2008; Hill et al. 2010) .
Antibiotic susceptibility of biofilms
Antibiotics were ineffective or inconsistent against biofilms of both bacterial species tested. None of the antibiotics tested were able to achieve >2 log reductions in both biofilm models. Tobramycin, cefepime and imipenem showed little efficacy against P. aeruginosa biofilms. While ciprofloxacin was somewhat effective against colony biofilms of P. aeruginosa (log reduction 3AE5), it performed poorly against drip-flow biofilms formed by the same strain (log reduction 0AE8). Amikacin was the most effective antibiotic for P. aerguinosa biofilms overall. Against MRSA biofilms, ampicillin, minocycline, vancomycin and daptomycin were completely ineffective. Only rifampicin at 100· MIC managed a fraction of a log reduction. These results show that these two in vitro biofilm models captured the antibiotic tolerance that is a hallmark of the biofilm mode of existence (Stewart and Costerton 2001) . We conclude that these are reasonable models for evaluating the antibiofilm efficacy of alternative therapeutic agents.
Bismuth thiol efficacy against biofilms
The thirteen different bismuth thiols tested under the conditions used in this investigation achieved widely varying degrees of killing, even against the same microorganism in the same biofilm model. For example, against P. aeruginosa colony biofilms, BisTol had no effect (log reduction )0AE3), whereas BisBAL left no surviving bacteria (log reduction > 7AE2). Similarly against MRSA colony biofilms, BisTOL had no effect (log kill )0AE1), whereas BisBDT ⁄ PYR recorded a 4AE9 log reduction. The differential efficacy of particular bismuth thiols between the two different micro-organisms is evident in Fig. 1 . What these results mean is that the choice of bismuth thiol needs to be tailored to the particular application.
For each micro-organism, the most effective bismuth thiol easily outperformed the most effective conventional antibiotic. For example, against P. aeruginosa biofilms, the most effective antibiotic was amikacin at 100 · MIC (1600 lg ml )1 ), which achieved a mean log reduction (averaging colony biofilm and drip-flow biofilm results) of 4AE1 BisBAL at 40 to 80 lg ml )1 achieved a >7AE7 log reduction for the same assays. Against MRSA biofilms, rifampicin at 100· MIC (0AE6 lg ml )1 ) achieved a mean log reduction of only 0AE7 BisBDT ⁄ PYR at 40-200 lg ml
achieved a mean log reduction of 4AE9 The most effective bismuth thiols also outperformed 1% silver sulfadiazine, a benchmark antimicrobial in treating wound infection (Akiyama et al. 1998; Bjarnsholt et al. 2007) . At 200 lg ml )1 , a typical bismuth thiol delivers approximately 0AE5 mmol l )1 bismuth. At 1% silver sulfadiazine, the concentration of silver is more than 50 times higher on a molar basis (28 mmol l )1 ). These results indicate that bismuth thiols may be competitive with existing antimicrobials for the treatment of bacteria in microbial biofilms. We tested for synergy between antibiotics and bismuth thiols. The only clear example of synergy was between amikacin and several bismuth thiols used against P. aeruginosa biofilms (Table 5) .
Two bismuth thiols stand out as particularly interesting based on our results: BisBAL and BisBDT ⁄ PYR. Numerous studies have found BisBAL to be a promising compound in a wide variety of applications. It has been reported to inhibit microbial growth on coated stents (Zhang et al. 2005) , reduce drinking water biofilms (Codony et al. 2003) and reduce virulence of P. aeruginosa (Wu et al. 2002) . BisBAL reportedly has low concentration MBCs for B. cepacia complex (Veloira et al. 2003 ) and a low MIC for E. coli. Huang and Stewart examined the effects of BisBAL on preformed biofilm of P. aeruginosa (Huang and Stewart 1999) and found that BisBAL at MIC concentration was able to kill biofilm cells of P. aeruginosa biofilms. In the current study, BisBAL was most effective against biofilms formed by P. aeruginosa and was the second most effective bismuth thiol against MRSA biofilms.
The other bismuth thiol of interest emerging from this study was one that has not been described in the literature before, BisBDT ⁄ PYR. This bismuth thiol was the best performing antimicrobial against established MRSA biofilms, which were highly recalcitrant to antibiotics. It also exhibited good activity against P. aeruginosa biofilms. The advanced efficacy demonstrated in this study suggests that additional investigation of a more expansive series of bismuth thiols against a broader range of disease-related biofilms is warranted.
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